drug_type
RELEVANT_DRUG
intervention_type
Biological (cellular therapy; CAR T cells)
drug_description
Genetically engineered CAR T-cell therapy that expresses dual chimeric antigen receptors targeting CD19 and CD22 to recognize and kill malignant B-ALL cells; administered intravenously at 1.0×10^6–10.0×10^6 CAR T cells/kg.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Genetically engineered T cells expressing dual chimeric antigen receptors targeting CD19 and CD22; antigen binding triggers CAR signaling (CD3ζ with costimulatory domains) to activate, expand, and mediate cytotoxic killing of malignant B‑ALL cells, mitigating antigen escape seen with single‑antigen CARs.
drug_name
B019
nct_id_drug_ref
NCT06927466